CB vs SGMO · P/E 14, rev $59.40B vs rev $57.8M
Chubb Ltd (CB) versus Sangamo Therapeutics Inc (SGMO) — a side-by-side from cached financials, not a winner call.
Chubb Ltd (CB) is a insurance - property & casualty company listed on US.
Sangamo Therapeutics Inc (SGMO) is a biotechnology company listed on NASDAQ.
Latest reported CB revenue for 2025-12-31 was $59.40B. Net income was $10.31B. Revenue was up 6.5% from 2024-12-31 to 2025-12-31. CB currently screens at market cap $114.26B and trailing P/E 13.7.
Latest reported SGMO revenue for 2024-12-31 was $57.8M. Net income was -$97.9M. Revenue was down 67.2% from 2023-12-31 to 2024-12-31. SGMO currently screens at market cap $74.6M.
CB currently screens at market cap $114.26B and trailing P/E 13.7. SGMO currently screens at market cap $74.6M.
Not investment advice. Open the CB and SGMO stock pages for the full models.
Not investment advice.